Jon Wigginton
Director/Board Member chez SUTRO BIOPHARMA, INC.
Fortune : - $ au 31/03/2024
Profil
Jon Marc Wigginton is currently an Independent Director at Sutro Biopharma, Inc., a Director at UbiVac, Inc., a Director at Kalivir Immunotherapeutics, Inc., and the President-Research & Development at Bright Peak Therapeutics AG.
Previously, he served as the Chairman-SAB at Cullinan Therapeutics, Inc., the Executive Director-Discovery Medicine-Clinical at Bristol Myers Squibb Co., the Director-Clinical Oncology at Merck Research Laboratories Massachusetts LLC, an Independent Director at Checkmate Pharmaceuticals, Inc., the Chief Medical Officer & SVP-Clinical Development at MacroGenics, Inc., and the Head-Investigational Biologics Section at the Center for Cancer Research.
He also held the position of Chief Medical Officer at Cullinan Oncology LLC and served as the President of the Society For Immunotherapy of Cancer.
Dr. Wigginton obtained undergraduate and doctorate degrees from the University of Michigan.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SUTRO BIOPHARMA, INC.
-.--% | 08/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Jon Wigginton
| Sociétés | Poste | Début |
|---|---|---|
| SUTRO BIOPHARMA, INC. | Director/Board Member | 30/11/2020 |
UbiVac, Inc.
 UbiVac, Inc. Pharmaceuticals: MajorHealth Technology UbiVac LLC engages in the research, development and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases. The company was founded by Bernard A. Fox and Hong-Ming Hu in 2005 and is headquartered in Portland, OR. | Director/Board Member | 15/10/2020 |
Kalivir Immunotherapeutics, Inc.
 Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | Director/Board Member | - |
Bright Peak Therapeutics AG
 Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | Chief Tech/Sci/R&D Officer | - |
Anciens postes connus de Jon Wigginton
| Sociétés | Poste | Fin |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/08/2022 |
| CHECKMATE PHARMACEUTICALS, INC. | Director/Board Member | 31/05/2022 |
| MACROGENICS, INC. | Chief Tech/Sci/R&D Officer | 27/03/2020 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The private company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Corporate Officer/Principal | - |
Formation de Jon Wigginton
| University of Michigan | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| SUTRO BIOPHARMA, INC. | Health Technology |
| MACROGENICS, INC. | Health Technology |
| CULLINAN THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The private company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Health Technology |
UbiVac, Inc.
UbiVac, Inc. Pharmaceuticals: MajorHealth Technology UbiVac LLC engages in the research, development and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases. The company was founded by Bernard A. Fox and Hong-Ming Hu in 2005 and is headquartered in Portland, OR. | Health Technology |
| Center for Cancer Research | Government |
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Cullinan Oncology LLC
 Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Finance |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | Health Technology |
Society For Immunotherapy of Cancer
 Society For Immunotherapy of Cancer Miscellaneous Commercial ServicesCommercial Services The Society for Immunotherapy of Cancer (SITC) is an organization that advances the science, development, and application of immunotherapy to improve cancer patient outcomes. The non-profit company is based in Milwaukee, WI. SITC conducts policy and advocacy efforts on behalf of its members and the field. The Journal for Immunotherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of SITC, featuring original research articles, literature reviews, position papers, and discussions on all aspects of tumor immunology and cancer immunotherapy. SITC also created a conceptual framework for potential value in phase III studies evaluating immunotherapy combinations. | Commercial Services |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | Health Technology |
